Targeting CDK2 in p16 Deficient Head and Neck Squamous Cell Carcinoma

Authors

Isha K. Thapar, Perelman School of Medicine at the University of PennsylvaniaFollow
Tsung-You Tsai, MD Anderson Department of Head and Neck SurgeryFollow
Mutsuki Kawabe, MD Anderson Department of Head and Neck SurgeryFollow
Jeffrey N. Myers, MD Anderson Department of Head and Neck SurgeryFollow
Abdullah A. Osman, MD Anderson Department of Head and Neck SurgeryFollow

Files

Description

In this study, we explored the therapeutic vulnerability of head and neck squamous cell carcinoma (HNSCC) cell lines to a novel CDK2 inhibitor, Tagtociclib.

Program Affiliation

Medical Students Summer in Oncology at Anderson Research (Med Students SOAR)

DOI

https://doi.org/10.52519/00160

Publication Date

8-8-2024

Recommended Citation

Thapar, Isha K.; Tsai, Tsung-You; Kawabe, Mutsuki; Myers, Jeffrey N.; and Osman, Abdullah A., "Targeting CDK2 in p16 Deficient Head and Neck Squamous Cell Carcinoma" (2024). Students Summer in Oncology at Anderson Research (SOAR). 11.
doi:https://doi.org/10.52519/00160